Mesenchymal stem cells (MSCs) have the capacity for self‐renewal and pluripotency, making them a primary candidate for cell‐based therapy. The purpose of this study was to
evaluate inhibition effect of Wharton Jelly derived MSC (WJ‐MSC) on the K562 cells as chronic myeloid leukemia (CML) cell lines. In this study, WJ‐MSCs were isolated from an umbilical
cord, and characterized by flow cytometry. WJ‐MSCs (1×104/cm2) were obtained from Passage 1, and plated into 24‐well plates in 1 ml DMEM complete culture medium solution.
WJ‐MSCs were incubated in a flask at 37˚C in a humidified air with 5% CO2. After 7 hours, K562 cells (1×105/ml) were added respectively K562: MSC; 1:2, 1:5, 1:10 ratio, low‐glucose
DMEM containing 10% FBS and 1% penicillin/streptomycin solution. The co‐culture was incubated 72 hours at 37˚C in 5% CO2, and the co‐cultured K562 cells were subsequently
separated from adherent WJ‐MSCs by slow and careful pipetting. The cell counts and viability were determined by trypan blue dye exclusion. The viable and non‐viable cells were
counted with a hemocytometer. The non‐viable cell percentages were compared as 1:2 (42%), 1:5 (52,2%), 1:10 (33,3%) and control plates (%7,69) (untreated K562 cell line) after 72
hours incubation. The most effective dose was found 1:5 (52,2%). In conclusion, the results showed that WJ‐MSCs can suppress K562 cell proliferation when using in proper ratio. This
study will provide perspective on the next projects. In the future, WJ‐MSCs may be an option for their clinic use for the inhibition of cancer cells.
Keywords: Cancer immunology, cellular interactions, stem cells